Regorafenib (Zebeshu) 40mg*28's | Jiangxi Kerui China | GLT

Generic Information: Zebeshu (China)

Zebeshu (泽贝舒) is a Chinese-market brand of regorafenib produced by Jiangxi Kerui Pharmaceutical Co., Ltd., a domestic manufacturer of oncology and specialty medicines. Each pack holds 28 film-coated tablets containing 40 mg of regorafenib. Zebeshu is a licensed, affordable alternative to the Bayer originator Stivarga for patients needing later-line treatment of advanced colorectal cancer, gastrointestinal stromal tumour or hepatocellular carcinoma.

What Is Regorafenib (Zebeshu) Used For?

Zebeshu is indicated for metastatic colorectal cancer that has progressed despite fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy plus anti-VEGF and, where relevant, anti-EGFR therapy. It is also used for gastrointestinal stromal tumour that is resistant to imatinib and sunitinib, and for hepatocellular carcinoma that has progressed on sorafenib. In every setting it is used to slow progression once earlier lines have stopped working.

How Does Regorafenib Work?

Regorafenib is a multi-kinase inhibitor that targets the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This broad action blocks both the growth signals inside cancer cells and the signalling that drives new blood-vessel formation, so tumours are deprived of both the instructions to divide and the blood supply they need to survive and spread.

Indications

The three approved indications are advanced colorectal cancer after standard chemotherapy, imatinib- and sunitinib-refractory gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. An oncologist should initiate and monitor treatment, and liver function and blood pressure must be assessed before starting.

Dosage

The recommended dose is 160 mg (four 40 mg tablets) once daily with a low-fat meal, given in 28-day cycles of 21 days on and 7 days off. A 28-tablet pack covers seven days of the active-treatment phase. The dose may be reduced to 120 mg or 80 mg daily to manage side effects such as hand-foot skin reaction or elevated liver enzymes.

Side Effects

The most frequent side effects are hand-foot skin reaction, diarrhoea, fatigue, high blood pressure, reduced appetite and mouth sores. Serious but uncommon effects include liver injury, bleeding, gastrointestinal perforation and cardiac problems. Liver function, blood pressure and blood counts should be monitored regularly, and patients should report skin changes, persistent diarrhoea, dark stools or chest pain promptly.

Storage

Store Zebeshu tablets at room temperature in the original container, protected from moisture, and out of the reach of children. Do not use past the expiry date shown on the pack.

Why Choose Zebeshu Through GLT?

Zebeshu gives overseas patients and institutions a dependable, lower-cost Chinese generic regorafenib for later-line cancer care. GLT sources directly from established domestic manufacturers and ships worldwide from a Hong Kong-licensed facility, helping patients keep treatment affordable over the weeks and months of therapy.

How to Order

To order Zebeshu (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

What is the dosing schedule? 160 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

How long does a 28-tablet pack last? Seven days of active dosing at the standard 160 mg daily dose.

Do I need a prescription? Yes, a valid prescription from a licensed oncologist is required.